POMC and pituitary tumor: Preclinical data demonstrated that targeting PD-L1 initiated effective antitumor immunity in aggressive ACTH-secreting pituitary tumors after reducing the plasmatic hormonal levels, decreasing tumoral volume while increasing survival rates.